Acute Lung Injury Market

Key Highlights

• The Acute Lung Injury market is expected to grow due to various factors, such as increasing incidence of Acute Lung Injury, growing awareness among healthcare professionals, and advancements in diagnostic techniques and treatment modalities.
• With the COVID-19 pandemic coming in, there was a significant rise in cases of ARDS overall 7MM, further leading to an increase in the Acute Lung Injury market.
• The exact  Acute Lung Injury market size is difficult to determine due to the heterogeneity of  Acute Lung Injury and its overlap with acute respiratory distress syndrome (ARDS). However, the  Acute Lung Injury market is expected to experience steady growth due to the increasing incidence of Acute Lung Injury.
•  Acute Lung Injury Market players like Asklepion Pharmaceuticals, LLC, Edesa Biotech, Direct Biologics, and others have developed their assets in the emergent market; however, due to the complex nature of Acute Lung Injury, the need for personalized treatment approaches and the high costs associated with research and development may pose obstacles to market expansion.

Request for unlocking the CAGR of the “Acute Lung Injury Market”

DelveInsight’s report titled “Acute Lung Injury Market Insights, Epidemiology, and Market Forecast - 2032” comprehensively analyzes Acute Lung Injury. The report includes a detailed examination of the historical and projected epidemiology data, including incident cases of Acute Lung Injury segmented by severity and risk factors. The report offers an in-depth understanding of the various aspects related to the patient population, including diagnosis, prescriptions patterns, physician perspectives, market access, treatment, and future market developments for the seven major markets, including the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan from 2019 to 2032.

To gauge the market’s overall potential and identify business opportunities, the report discusses current Acute Lung Injury treatment practices and algorithms as well as unmet medical needs.

Acute Lung Injury Overview

Acute Lung Injury is a condition characterized by inflammation and lung damage, resulting in impaired gas exchange and respiratory failure. It is considered a severe form of lung injury and can occur due to various causes, including infections, trauma, inhalation of toxic substances, and sepsis. American–European Consensus Conference set the criteria to define Acute Lung Injury and Acute Respiratory Distress Syndrome in research and clinical medicine. They distinguished between ALI and ARDS based upon the degree of hypoxemia present, as determined by the ratio of partial pressure of arterial oxygen to fractional inspired oxygen concentration (PaO₂/FiO₂), with ALI patients demonstrating a milder level of hypoxemia.

Acute Lung Injury Diagnosis and Treatment Algorithm 

The diagnosis of Acute Lung Injury (ALI) involves a comprehensive assessment that includes a thorough medical history, physical examination, imaging studies such as chest X-ray or CT scan to evaluate lung abnormalities, measurement of blood oxygen levels using pulse oximetry or arterial blood gas analysis, laboratory tests to identify underlying causes or infections, and sometimes pulmonary function tests to assess lung function. 

The management of ALI involves treating the underlying cause, providing supportive care, and ensuring adequate oxygenation. This may include mechanical ventilation to assist with breathing, supplemental oxygen therapy, and medications to reduce inflammation. In severe cases, patients may require admission to an intensive care unit (ICU) for close monitoring and advanced respiratory support.

Acute Lung Injury Epidemiology

The Acute Lung Injury epidemiology section provides insights into the historical and current Acute Lung Injury patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, its trends, and assumptions undertaken.

The epidemiology section of the Acute Lung Injury report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

Key Findings

• According to Bellani et al. (2016), in a multicenter prospective study carried out in 459 ICUs in 50 countries on five continents, ARDS represented 10.4% of the total admission to ICU and 23.4% of all patients requiring mechanical ventilation. The prevalence was 30.0% for mild ARDS, 46.6% for moderate ARDS, and 23.4% for severe ARDS, and overall, unadjusted ICU and hospital mortality were 35.3% and 40.0%, respectively.
• According to Rubenfeld et al. (2005), the crude incidence of ALI was 78.9 per 100,000 person-years, and the age-adjusted incidence was 86.2 per 100,000 person-years. The in-hospital mortality rate was 38.5%. The incidence of ALI increased with age, from 16 per 100,000 person-years for those 15–19 years of age to 306 per 100,000 person-years for those 75–84 years of age. Mortality increased with age, from 24% for patients 15–19 years of age to 60% for patients 85 or older. 
• According to another paper by Mackay et al. (2009), the incidence of ALI is quoted to be between 17 and 34 per 100,000 patients per year. About 16% of all patients ventilated in the ICU for 24 h or more develop ALI. These patients have high mortality, thus proving the severity of the primary pathology causing ALI, other associated organ failures, and complications associated with a critical illness.
• According to a prospective study by Bossier et al. (2013), there was about a 22% incidence of aPH in a regular ALI or ARDS population. The presence of aPH (as determined by pulmonary artery catheterization) was associated with a 60% 28-day mortality, in contrast to 36% in patients without aPH. 
• According to another paper by Johnson and Matthay (2010), predisposing clinical factors for ALI include sepsis, pneumonia, aspiration, trauma, pancreatitis, blood transfusions, and smoke or toxic gas inhalation. Sepsis had a higher mortality than major trauma (43% vs. 11%), whereas pneumonia and aspiration are intermediate risk factors (36% and 37%, respectively)

Pneumonia, Sepsis, Trauma, Aspiration, Pancreatitis, Covid-19, and others are the risk factors taken into account by DelveInsight’s analysts to calculate the incident cases of Acute Lung Injury by risk factors.

Acute Lung Injury Market Outlook

The current treatment approach for Acute Lung Injury involves a combination of supportive care, addressing the underlying cause, and managing complications, such as administering antibiotics for infections or addressing sepsis; other interventions include the use of anti-inflammatory medications, such as corticosteroids and managing complications such as sepsis and organ dysfunction.

The current therapies have only been useful in addressing ALI-associated inflammation, but none treat impaired lung function. Consequently, there is a significant unmet medical need and market opportunity for developing new therapeutics that treat the underlying pathogenesis of ALI. Several randomized controlled trials of pharmacological compounds have been accomplished for the adjuvant therapy of ALI. However, no success has been recorded to date for the management of ALI. The mechanism to inhibit ROS/NLRP3 is under study. ROS/NLRP3 inhibitor treatment protects against LPS‑induced acute lung injury by inhibiting ROS/NLRP3‑dependent pyroptosis and apoptosis via the Nrf2 signaling pathway. EB05, toll-like receptor 4 (TLR4) signaling inhibitor- an important mediator of inflammation responsible for acute lung injury that is activated by SARS-CoV2, SARS-CoV1, and Influenza viruses, has been gaining interest as a potential biomarker for ALI and may have therapeutic potential. Emerging treatments for Acute Lung Injury (ALI) are being investigated and show promise in improving patient outcomes. One area of focus is using novel pharmacological agents targeting specific pathways involved in lung inflammation, such as anti-inflammatory cytokines, antioxidants, and immunomodulatory agents. Furthermore, advancements in precision medicine and personalized therapies hold the potential for tailored approaches based on individual patient characteristics.

According to DelveInsight’s, the Acute Lung Injury market in the 7MM is expected to change during the study period 2019–2032 significantly.

Acute Lung Injury Drug Chapters 

Emerging Drugs

The therapeutic treatments currently available in the landscape of Acute Lung Injury aim to mitigate the complications associated with the condition. The Acute Lung Injury market dynamics are expected to undergo changes in the future, primarily due to increased healthcare spending worldwide. Market players such as Asklepion Pharmaceuticals, LLC, Edesa Biotech, and others are actively involved in developing Acute Lung Injury treatments. 

L-citrulline: Asklepion Pharmaceuticals, LLC

Citrulline protects against LPS‑induced acute lung injury by inhibiting ROS/NLRP3‑dependent pyroptosis and apoptosis via the Nrf2 signaling pathway. The company is evaluating this drug in Phase III to prevent clinical sequel of acute lung injury in pediatric patients undergoing cardiopulmonary bypass for surgical correction of heart defects.

EB05: Edesa Biotech 

EB05 is an experimental monoclonal antibody that Edesa believes could regulate the overactive and dysfunctional immune response associated with Acute Respiratory Distress Syndrome (ARDS). The drug inhibits toll-like receptor 4 (TLR4) signaling - an important mediator of inflammation responsible for acute lung injury that is activated by SARS-CoV2, SARS-CoV1, and Influenza viruses.

Acute Lung Injury Market Segmentation

DelveInsight’s ‘Acute Lung Injury – Market Insights, Epidemiology, and Market Forecast – 2032’ report provides a detailed outlook of the current and future Acute Lung Injury market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Market Size by Countries

The total market of Acute Lung Injury is analyzed for individual countries (the United States Market, EU4 (Germany, France, Italy, and Spain) and the UK market, and Japan). The United States accounted for a larger portion of the 7MM market for Acute Lung Injury in 2022 due to the high prevalence of the condition and the higher cost of treatments. This dominance is predicted to continue with the potential early entry of new products.

Market Size by Therapies

Acute Lung Injury is challenging due to the complex nature of the condition; however, the existing therapies for Acute Lung Injury are indeed low-cost and readily available, limiting the market size.  These include anti-inflammatory medications, such as corticosteroids and immunomodulatory agents, commonly used to mitigate the inflammatory response. Additionally, supportive care measures like mechanical ventilation, oxygen therapy, and fluid management contribute to the overall market size. Emerging therapies, including novel pharmacological agents targeting specific pathways and stem cell therapies, have the potential to expand the market further as it is expected that these will have a higher cost ratio, and if proven effective, physician and patient’s acceptance will be improved. Of all the above factors, the market will likely expand to multiple folds in the near future.

Acute Lung Injury Drugs Uptake

This section focuses on the sales uptake of potential drugs that have recently launched or are anticipated to be launched in the Acute Lung Injury market between 2019 and 2032. It estimates the market penetration of the drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the market.

The emerging therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the market.

Acute Lung Injury Market Access and Reimbursement

DelveInsight’s ‘Acute Lung Injury – Market Insights, Epidemiology, and Market Forecast – 2032’ report provides a descriptive overview of the market access and reimbursement scenario of Acute Lung Injury.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments. 

Acute Lung Injury Pipeline Development Activities

The report provides insights into therapeutic candidates in Phase II and III stages. It also analyses Acute Lung Injury key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers collaborations, acquisition and merger, licensing, patent details, and other information for emerging Acute Lung Injury therapies.

Acute Lung Injury KOL Views

To keep up with current market trends and fulfill gaps in secondary findings, we interview KOLs and SMEs’ working in the Acute Lung Injury domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or Acute Lung Injury market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Acute Lung Injury: KOL Insights

DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as Stanford University School of Medicine in the US, University of Angers in France, and others.

“Acute Lung Injury is a severe and potentially life-threatening condition. The mortality rate associated with ALI remains relatively high, ranging from 25% to 40%.” 

Note: Detailed assessment of KOL Views will be provided in the full report of Acute Lung Injury.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Acute Lung Injury Market using various Competitive Intelligence tools, including SWOT analysis, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Acute Lung Injury Report Insights

• Patient Population
• Therapeutic Approaches
• Acute Lung Injury Pipeline Analysis
• Acute Lung Injury Market Size and Trends
• Market Opportunities
• Impact of Upcoming Therapies

Acute Lung Injury Report Key Strengths

• Acute Lung Injury 10 Years Forecast
• 7MM Coverage
• Acute Lung Injury Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Acute Lung Injury Drugs Uptake

Acute Lung Injury Report Assessment

• Acute Lung Injury Current Treatment Practices
• Unmet Needs
• Acute Lung Injury Pipeline Product Profiles
• Acute Lung Injury Market Attractiveness

Key Questions

• What are the key findings of the market across 7MM, and what country will have the largest Acute Lung Injury market size during the forecast period (2023–2032)?
• What are the risk factors for developing acute lung injury? Can acute lung injury be prevented?
• At what CAGR is the Acute Lung Injury market, and is epidemiology expected to grow in the 7MM during the forecast period (2023-2032)?
• In what ways would the unmet needs impact market dynamics and subsequently influence the analysis of related trends? Are there any approved medications specifically for Acute Lung Injury?
• What would be the forecasted patient pool of Acute Lung Injury in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• What is the outlook for the Acute Lung Injury market? 
• What is the difference between acute lung injury (ALI) and acute respiratory distress syndrome (ARDS)?